Cytotoxicity Activity, Metabolite Profiling, and Isolation Compound from Crude Hexane Extract of Cleome rutidospermae

Document Type : Research Articles


1 Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, 90242, Indonesia.

2 Department of Pharmacognosy-Phytochemistry Laboratory, Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia.

3 Faculty of Health Sciences, Almarisah Madani University, Makassar, 90245, Indonesia.

4 School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.

5 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, 55281, Indonesia.


Objective: This study isolated the chemical compounds and evaluated the cytotoxic activity of the crude hexane extract of Cleome rutidospermae herb (CRH). Methods: The isolate was purified using silica gel, column chromatography, and preparative thin layer chromatography (PTLC). Furthermore, the structure of the compounds was identified by spectroscopic methods using 1D, 2D NMR, and mass spectrometry. The cytotoxic activity of CRH at a concentration of 20 ug/mL was also tested against MCF-7, A549, KB, KB-VIN, and MDA-MB-231 cancer cells using the sulforhodamine B (SRB) method. Results: The CRH contained compounds of unsaturated fatty acid, saturated fatty acid, lipid, glycerol, ω-3 fatty acid, and cholesterol. Two compounds were obtained from the plant, and their structures were identified as (1) Stigmasta-5,22-dien-3-ol (STML) and (2) 1,2-Benzene dicarboxylic acid, 1,2-bis (2-Ethylhexyl) esters (DEHP). These compounds were reported in this plant for the first time. In comparison, CRH had % growth inhibition in the proliferation of MCF-7 cells up to 28.1%, with cancer cells A549, KB, KB-VIN, and MDA-MB-231 by >50% Compared to the negative DMSO of 0.20%, while the positive control could inhibit the growth of all cancer cells (100%). Conclusion: Our findings suggested that crude herb from the plant CRH was the potential for breast cancer treatment.


Main Subjects

Volume 24, Issue 10
October 2023
Pages 3345-3352
  • Receive Date: 21 October 2021
  • Revise Date: 01 November 2022
  • Accept Date: 22 October 2023
  • First Publish Date: 22 October 2023